Drug intelligence / Profile preview

TSA-CTL

Development stage: Phase 1
Lead developer: BGI
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TSA-CTL is a form of adoptive cell therapy that uses cytotoxic T lymphocytes engineered to target tumor-specific antigens. The therapy involves collecting a patient's T cells, engineering them to recognize tumor-specific antigens, and then reinfusing these cells back into the patient to target and kill cancer cells. It is being investigated for the treatment of advanced solid tumors, particularly melanoma.

Other names: Tumor Specific Antigen-Cytotoxic T Lymphocyte

Beyond the preview

Go deeper on TSA-CTL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSA-CTL.

Explore the full profile